# Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

> **NCT03235869** · EARLY_PHASE1 · WITHDRAWN · sponsor: **University of Michigan Rogel Cancer Center**

## Conditions studied

- Cutaneous T Cell Lymphoma

## Interventions

- **DRUG:** Durvalumab
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03235869
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The company pulled durvalumab from heme malignancies
- **Last updated:** 2018-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03235869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03235869, "Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03235869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*